Replies to post #102812 on Biotech Values

[jq1234]

Ixebepilone, which sees very little use in 3rd line BCa from what I'm told, is likely the reason why this got hung up.

I looked at T-DM1 3rd line result more closely today. I don't see patients in this trial used gemcitabine before. So, at least two approved MBC treatments not used in study population.